Entity

Time filter

Source Type

Tianjin, China

Yang R.,Hubei Cancer Hospital | Yang R.,Huazhong University of Science and Technology | Zhang Y.,Huazhong University of Science and Technology | Zhou H.,Huazhong University of Science and Technology | And 5 more authors.
Therapeutic Drug Monitoring | Year: 2016

Recent studies suggest that 5-fluorouracil (5-FU) dosing by use of pharmacokinetic (PK) parameters is superior to the traditional body surface area (BSA) method in colorectal cancer therapy. The purpose of this study was to compare the estimated efficacy and toxicity of the use of PK-guided versus BSA-based dose adjustment of 5-FU in advanced cancers. Methods: The authors searched from electronic databases (up to September, 2014) and abstracts presented at the American Society of Clinical Oncology held between 2000 and 2014 for studies comparing the response rate and toxicity in 5-FU-based chemotherapy. Results: Five eligible articles with 654 patients were included in double-arms and contained colorectal cancer, and head and neck cancer. PK-monitored 5-FU therapy was associated with significant improvement in overall response rate (odds ratio = 2.04, 95% confidence interval, 1.41-2.95, Z = 3.78, P = 0.0002) compared with the traditional BSA method. There was no evidence of improved tolerability: grade 3 to 4 diarrhea, neutropenia, and hand-foot syndrome were found not to be significantly different except that mucositis was less prominent for PK-monitored 5-FU therapy (odds ratio = 0.16, 95% confidence interval, 0.04-0.63, Z = 2.62, P = 0.009). Conclusions: In comparison with conventional BSA method, PK-based 5-FU dosage confirmed a superior overall response rate and improved toxicities irrespective of significant difference, the results of which indicated that PK-monitored 5-FU dosage has the potential to be performed in colorectal cancer personalized therapy. More high-quality and multicenter randomized controlled trails should be carried out to provide more information for comparing the response and toxicity of these 2 dose adjustment methods. © 2015 Wolters Kluwer Health, Inc. Source


Li L.,Zhejiang Provincial Peoples Hospital | Wang Y.-Y.,Gastrointestinal Surgery | Zhao Z.-S.,Zhejiang Provincial Peoples Hospital | Ma J.,Zhejiang Provincial Peoples Hospital
Pathology and Oncology Research | Year: 2011

To investigat the clinical significance of Ezrin in the development and progression of gastric cancer. Immunohistochemistry was employed to analyze Ezrin expression in 436 clinicopathologically characterized gastric cancer cases. Ezrin protein levels were up-regulated in gastric cancer lesions compared with adjacent noncancerous tissues. Positive expression of Ezrin correlated with age, size of tumor, location of tumor, depth of invasion, vessel invasion, lymph node and distant metastasis and TNM stage. In stages I, II and III, the 5 year survival rate of patients with a high expression of Ezrin was significantly lower than those in patients with low expression. In stage IV, Ezrin expression did not correlate with the 5 year survival rate. Further multivariate analysis suggested that the depth of invasion, lymph node and distant metastasis, TNM stage, and up-regulation of Ezrin were independent prognostic indicators for the disease. Expression of Ezrin in gastric cancer is significantly associated with lymph node and distant metastasis, and poor prognosis. Ezrin protein could be useful markers to predict tumor progression and prognosis. © Arányi Lajos Foundation 2011. Source


Jing C.,General Hospital of Chengdu Military Area | Huang Z.-J.,General Hospital of Chengdu Military Area | Duan Y.-Q.,General Hospital of Chengdu Military Area | Wang P.-H.,Gastrointestinal Surgery | And 3 more authors.
Asian Pacific Journal of Cancer Prevention | Year: 2012

Aim: To evaluate the association of glutathione S-transferases gene polymorphisms with the risk of gastric cancer, with reference to smoking and Helicobacter pylori infection. Methods: We conducted a 1:1 matched casecontrol study with 410 gastric cancer cases and 410 cancer-free controls. Polymorphisms of GSTM1, GSTT1 and GSTP1 were determined using PCR-CTPP. Results: The GSTM1 and GSTT1 null genotypes were significantly associated with the risk of gastric cancer after adjusting for potential confounding factors (OR=1.68, 95% CI=1.32-2.23 for null GSTM1, OR=1.73; 95% CI=1.24-2.13 for null GSTT1). The combination of null GSTM1 and null GSTT1 conferred an elevated risk (OR=2.54, 95% CI=1.55-3.39). However, no association was found for GSTP1 polymorphism The smoking modified the association of GSTM1 and GSTT1 null genotypes with the risk of gastric cancer. Conclusion: GSTM1 and GSTT1 null genotypes are associated with increased risk of gastric cancer, and smoking modifies the association. Source


Chen J.,The General Hospital of Chengdu Military Area | Huang Z.-J.,The General Hospital of Chengdu Military Area | Duan Y.-Q.,The General Hospital of Chengdu Military Area | Xiao X.-R.,The General Hospital of Chengdu Military Area | And 2 more authors.
Asian Pacific Journal of Cancer Prevention | Year: 2012

Aim: The present case-control study was conducted to explore the association of MTHFR gene polymorphism and relations of P16, MGMT and HMLH1 to MTHFR and folate intake. Methods: A total of 257 cases of esophageal squamous cell carcinoma confirmed by histopathologicalexamination were collected. Genotyping of P16, MGMT and HMLH1 was accomplished by methylation-specific polymerase chain reaction (PCR) after sodium bisulfate modification ofDNA and the MTHFR C677T genetic polymorphism was detected by PCRrestriction fragment-length polymorphism (PCR-RFLP). Results: The proportions of DNA hypermethylation in P16, MGMTandhMLH1 in cancer tissues were significantly higher than in paracancerous normal tissue.The proportion of hypermethylation in at least one gene was 88.5% in cancer tissue, and wasalso significantly higher than that in paracancerous normal tissue. Our finding showed individuals with homozygotes (TT) of MTHFR C677T had significant risk of DNA hypermethylation of MGMT in cancer tissues, with an OR (95% CI) of 3.15 (1.12-6.87). Similarly, patients with high intake of folate also showed a slight high risk of DNA methylation of MGMT,with OR (95% CI) of 2.03 (1.05-4.57). Conclusion: Our study found the P16, MGMT and hMLH1demonstrate a high proportion of hypermethylation in esophageal squamous cell cancer cancer tissues, which might be used as biomarkers for cancer detection. © The Korean Pain Society, 2012. Source


Liang T.-J.,Shandong University | Liu H.,Shandong University | Zhao X.-Q.,Shandong University | Tan Y.-R.,Shandong University | And 2 more authors.
Tumor Biology | Year: 2014

Methylenetetrahydrofolate reductase (MTHFR) is one of the most important enzymes for folate metabolism which plays a key role in cell metabolism. MTHFR rs1801131 (A1298C) polymorphism can decrease in vitro MTHFR enzyme activity and has been hypothesized to be associated with liver cancer risk. This study aimed to quantify the strength of the association between MTHFR rs1801131 polymorphism and liver cancer risk by performing a meta-analysis. We searched the PubMed and Wanfang databases for studies relating on the association between MTHFR rs1801131 polymorphism and risk of liver cancer. Seven studies with 2,030 cases of liver cancer and 3,096 controls were finally included into the meta-analysis. Meta-analysis of a total of seven studies showed that the homozygote genotype CC of MTHFR rs1801131 polymorphism was significantly associated with decreased risk of liver cancer (for CC versus AA: odds ratio (OR)=0.65, 95% confidence interval (CI) 0.47-0.89, P=0.007; for CC versus AA+AC: OR=0.65, 95 % CI 0.48-0.89, P=0.006). Subgroup by race showed that the homozygote genotype CC of MTHFR rs1801131 polymorphism was significantly associated with decreased risk of liver cancer in Asians (CC versus AA: OR=0.64, 95 % CI 0.46-0.90, P=0.010; for CC versus AA+ AC: OR=0.63, 95 % CI 0.45-0.88, P=0.007). However, the association in Caucasians was still unclear owing to the limited data available now. Thus, Asian individuals with the homozygote genotype CC of MTHFR rs1801131 polymorphism are significantly associated with decreased risk of liver cancer. The association in Caucasians needs further studies. Source

Discover hidden collaborations